» Articles » PMID: 10685762

The Cost of Hospitalization in Crohn's Disease

Overview
Specialty Gastroenterology
Date 2000 Feb 24
PMID 10685762
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to evaluate the demographics, resource use, and costs associated with hospitalization of Crohn's disease patients.

Methods: All patients hospitalized at our institution from 7/1/96 to 6/30/97 with a primary diagnosis of "Crohn's Disease" were analyzed using a computerized database. Data are presented "per hospitalization."

Results: A total of 175 hospitalizations (147 patients) were identified. Mean patient age was 36.5 yr; 61% were female; 82% Caucasian. Payer mix was most commonly contracted (57%), commercial (21%), or Medicare (13%). 57% of hospitalizations had a primary surgical procedure; the remainder were medical. Average length of stay was 8.7 days (surgical, 9.6 days; medical, 7.5 days). The average cost of hospitalization, excluding physician fees, was $12,528 (surgical, $14,409; medical, $10,020), whereas average charges were $35,378 (surgical, $46,354; medical, $20,744), including physician fees, which averaged $7,249 (surgical, $11,217; medical, $1,959). Mean reimbursements were $21,968 (surgical, $28,946; medical, $12,666) with average weighted reimbursement rates of 60.17% of hospital charges, 69.57% of physician fees. The distribution of costs across subcategories was: Surgery (39.6%), Pharmacy (18.6%), Laboratory (3.8%), Radiology (2.1%), Pathology (0.8%), Endoscopy (0.3%), and Other Hospital Costs (34.9%). Of the hospitalizations, 87% included treatment with steroids, 23% with immunomodulators, and 14% with aminosalicylates; 27% included the administration of total parenteral nutrition, which accounted for 63% of the total pharmacy costs.

Conclusions: Surgery accounts for the majority of hospitalizations, nearly 40% of their total costs, and 75% of overall charges and reimbursements. Therapy that decreases the number of surgical hospitalizations should substantially reduce inpatient Crohn's disease costs, as well as overall costs.

Citing Articles

Delayed Corticosteroid Treatment for Patients Requiring Hospitalization for Acute Inflammatory Bowel Disease Exacerbations Increases Length of Stay and Risk for Surgery in Crohn's Disease.

Vasudevan J, Mukkamala B, Dhother B, Guzik P, Tang Z, Feagins L Dig Dis Sci. 2025; .

PMID: 39948278 DOI: 10.1007/s10620-025-08907-1.


Treat to target in Crohn's disease: A practical guide for clinicians.

Srinivasan A World J Gastroenterol. 2024; 30(1):50-69.

PMID: 38293329 PMC: 10823901. DOI: 10.3748/wjg.v30.i1.50.


Hospital Cost of Inflammatory Bowel Disease and Its Determinants in a Multicenter Study From Iran.

Ghahramani S, Shojaadini H, Akbarzade A, Sadeghi F, Hajianpour V, Nozaie F Middle East J Dig Dis. 2023; 15(3):167-174.

PMID: 38023468 PMC: 10660313. DOI: 10.34172/mejdd.2023.339.


Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn's Disease.

Dulai P, Wan Y, Huang Z, Luo M Crohns Colitis 360. 2023; 4(4):otac048.

PMID: 36778514 PMC: 9802432. DOI: 10.1093/crocol/otac048.


Delayed Initiation of Rescue Therapy Associated with Increased Length of Stay in Acute Severe Ulcerative Colitis.

Caplan A, McConnell R, Velayos F, Mahadevan U, Lewin S Dig Dis Sci. 2022; 67(12):5455-5461.

PMID: 35389167 PMC: 9652198. DOI: 10.1007/s10620-022-07490-z.